↓ Skip to main content

Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

Overview of attention for article published in New England Journal of Medicine, March 2018
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (99th percentile)
  • Good Attention Score compared to outputs of the same age and source (75th percentile)

Readers on

mendeley
688 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.

Login to access the Attention Digest and the Sentiment Analysis related to this output.

Timeline Attention over time Attention Score history
Login to access the full charts related to this output.
Activity
Login to access the full charts related to this output.
X Demographics

X Demographics

The data shown below were collected from the profiles of 153 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley demographics

Mendeley demographics

The data shown below were compiled from readership statistics for 688 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Login to view Mendeley reader trends over time.

Geographical breakdown

Geographical breakdown
Country Count As %
Unknown 688 100%

Demographic breakdown

Readers by professional status
Readers by professional status Count As %
Researcher 78 11%
Other 74 11%
Student > Ph. D. Student 64 9%
Student > Bachelor 54 8%
Student > Doctoral Student 51 7%
Other 105 15%
Unknown 262 38%
Readers by discipline
Readers by discipline Count As %
Medicine and Dentistry 232 34%
Biochemistry, Genetics and Molecular Biology 73 11%
Pharmacology, Toxicology and Pharmaceutical Science 35 5%
Agricultural and Biological Sciences 28 4%
Immunology and Microbiology 13 2%
Other 32 5%
Unknown 275 40%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 310. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 August 2026.
All research outputs
#140,941
of 34,826,519 outputs
Outputs from New England Journal of Medicine
#3,213
of 38,787 outputs
Outputs of similar age
#2,805
of 377,035 outputs
Outputs of similar age from New England Journal of Medicine
#66
of 267 outputs
Altmetric has tracked 34,826,519 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 38,787 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 120.0. This one has done particularly well, scoring higher than 91% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 377,035 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 267 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 75% of its contemporaries.